MARKET

CDXC

CDXC

Chromadex Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.780
0.000
0.00%
Opening 15:54 07/06 EDT
OPEN
1.760
PREV CLOSE
1.780
HIGH
1.860
LOW
1.760
VOLUME
198.18K
TURNOVER
212.71K
52 WEEK HIGH
10.54
52 WEEK LOW
1.510
MARKET CAP
121.64M
P/E (TTM)
-4.4180
1D
5D
1M
3M
1Y
5Y
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Benzinga · 06/23 16:29
Trade Alert: Hoi Shuen Chau At ChromaDex Corporation (NASDAQ:CDXC), Has Just Spent US$100k Buying A Small Number of Shares
Even if it's not a huge purchase, we think it was good to see that Hoi Shuen Chau, a ChromaDex Corporation...
Simply Wall St. · 06/22 10:07
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
LOS ANGELES, June 15, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferenc...
Business Wire · 06/15 10:34
ChromaDex teams up with Sinopharm for sales of anti-ageing product in China
Life sciences company ChromaDex Corporation (NASDAQ:CDXC) announced an agreement with Sinopharm Xingsha, the health supplement division of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY) on Friday to speed up sales of its anti-ageing
Seekingalpha · 06/10 11:06
BRIEF-ChromaDex Signs Sinopharm Xingsha Agreement To Accelerate Cross-Border Sales Of Tru Niagen Into Mainland China
reuters.com · 06/10 10:36
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
LOS ANGELES, June 10, 2022--ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen® into ma...
Business Wire · 06/10 10:32
ChromaDex Signs Tru Niagen Distribution Deal With Sinopharm Xingsha; Shares Climb Premarket
MT Newswires · 06/10 07:08
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
LOS ANGELES, June 07, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference.
Business Wire · 06/07 17:33
More
No Data
Learn about the latest financial forecast of CDXC. Analyze the recent business situations of Chromadex Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CDXC stock price target is 7.56 with a high estimate of 11.00 and a low estimate of 5.75.
High11.00
Average7.56
Low5.75
Current 1.780
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 110
Institutional Holdings: 21.03M
% Owned: 30.77%
Shares Outstanding: 68.33M
TypeInstitutionsShares
Increased
18
2.09M
New
12
298.70K
Decreased
31
1.71M
Sold Out
13
616.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.41%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chief Executive Officer/Director
Robert Fried
Chief Financial Officer
Kevin Farr
Independent Director
Ann Cohen
Independent Director
Gary Ng
Independent Director
Kristin Patrick
Independent Director
Steven Rubin
Independent Director
Wendy Yu
No Data
No Data
About CDXC
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Webull offers kinds of Chromadex Corp stock information, including NASDAQ:CDXC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXC stock methods without spending real money on the virtual paper trading platform.